Close

Trichomonas vaginalis

Trichomonas vaginalis is an anaerobic, flagellated protozoan parasite and the most common curable STD. The World Health Organization (WHO) estimates that 170-190 million cases of infection are acquired annually worldwide and are increasing each year. As a result, T. vaginalis is receiving more attention, prompting an increased demand for both diagnosis of trichomoniasis and screening for asymptomatic infections.

Have questions about a product?

Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!

Contact A Specialist
Filter By:
Clear Results
4 Results
Name
Type
Format
Host/Source
Isotype
Tested Apps
Unit
Catalog
SDS
COA
Request Sample
MAb to Trichomonas Vaginalis
Monoclonal
Purified
Mouse
IgG1
IFA
MG
C01567M
MAb to Trichomonas Vaginalis
Monoclonal
Purified
Mouse
IgG3
EIA, IFA, Pr
MG
C01571M
MAb to Trichomonas Vaginalis
Monoclonal
Purified
Mouse
IgG3
EIA, IFA, Pr
MG
C01568M
MAb to T.vaginalis, p65
Monoclonal
Purified
Mouse
IgG1
EIA, IFA, IHC, LF
MG
C65675M

Trichomonas vaginalis

Trichomonas vaginalis is a single cell flagellum parasite that lives in the female vagina and the male urethra. Infections are transmitted directly when the organism moves from one host to another, usually during sexual contact. It has long been recognized as a common cause of vaginitis, known as trichomoniasis. Infection of the female genital tract can result in cervicitis, urethritis, and adverse pregnancy outcomes including prostatic secretions, fission of urethra, premature rupture of membranes, and low birth weight babies. Though it was once virtually ignored, T. vaginalis infection in men is now recognized as an important cause of nongonococcal urethritis and is associated with prostatitis and male infertility. In addition, trichomoniasis is a risk factor for sexual transmission of HIV. It has been demonstrated to play a critical role in amplifying HIV transmission by lowering the barrier of access to lymphocytes and macrophages.

Diagnosis

Approximately 70% of women with T. vaginalis do not exhibit symptoms and consequently diagnosis based on clinical symptoms alone is unreliable. The most commonly used method of diagnosis is direct microscopic observation (wet mount) of vaginal secretions and although both rapid and inexpensive, the sensitivity of this technique is generally very low (50 to 70%). Newer methods, such as rapid antigen testing and transcription-mediated amplification, have demonstrated greater sensitivity, often detecting 3-5x more T. vaginalis infections than wet-mount microscopy. Assays that can be used for self-testing are increasing in popularity due to the ease of use and convenience.

Screening of asymptomatic women with HIV infection for T. vaginalis is recommended because of the adverse events associated with asymptomatic trichomoniasis and HIV infection. Screening should also be considered for persons receiving care in high-prevalence settings (e.g., STD clinics and correctional facilities) and for asymptomatic persons at high risk for infection.

Get In Touch With A Specialist

Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!

By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our Privacy Statement.

Learn More About Us

Learn More

Welcome to

Please select your country to continue

Continue
EN